Jiangsu Nhwa Pharmaceutical Co., Ltd.
Shenzhen Stock ExchangeTotal Valuation
Jiangsu Nhwa Pharmaceutical Co., Ltd. carries a market capitalization of 20.77B, placing it among publicly traded companies globally. Its enterprise value stands at 17.19B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 20.77B |
| Enterprise Value | 17.19B |
Share Statistics
Jiangsu Nhwa Pharmaceutical Co., Ltd. currently has 1.02B shares outstanding.
| Shares Outstanding | 1.02B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Jiangsu Nhwa Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 17.14. The price-to-sales ratio is 3.50, and the price-to-book ratio stands at 2.98.
| PE Ratio | 17.14 |
| PS Ratio | 3.50 |
| PB Ratio | 2.98 |
| P/TBV Ratio | 2.89 |
| P/FCF Ratio | 53.12 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Jiangsu Nhwa Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 12.49 and an EV/FCF ratio of 43.56. The EV/Sales ratio of 2.89 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 12.49 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.89 |
| EV / EBITDA | 12.49 |
| EV / EBIT | 12.49 |
| EV / FCF | 43.56 |
Financial Position
Jiangsu Nhwa Pharmaceutical Co., Ltd. maintains a current ratio of 6.05, meaning it holds 6.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.10, indicating moderate leverage, while an interest coverage ratio of 470.20 demonstrates strong ability to service its debt obligations.
| Current Ratio | 6.05 |
| Quick Ratio | 3.51 |
| Debt / Equity | 1.10 |
| Debt / EBITDA | 0.06 |
| Interest Coverage | 470.20 |
Financial Efficiency
Jiangsu Nhwa Pharmaceutical Co., Ltd. posts a return on equity of 18.54 and a return on invested capital of 16.60.
| Return on Equity (ROE) | 18.54 |
| Return on Assets (ROA) | 14.79 |
| Return on Invested Capital (ROIC) | 16.60 |
| Return on Capital Employed (ROCE) | 18.36 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.30 |
Taxes
Over the trailing twelve months, Jiangsu Nhwa Pharmaceutical Co., Ltd. has paid 149.83M in income taxes, reflecting an effective tax rate of 10.98.
| Income Tax | 149.83M |
| Effective Tax Rate | 10.98 |
Stock Price Statistics
Jiangsu Nhwa Pharmaceutical Co., Ltd.'s stock has declined approximately -4.03566% over the past 52 weeks. The 50-day moving average sits at 20.39, while the 200-day moving average is 23.22.
| Beta (5Y) | N/A |
| 52-Week Price Change | -4.03566% |
| 50-Day Moving Average | 20.39 |
| 200-Day Moving Average | 23.22 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Jiangsu Nhwa Pharmaceutical Co., Ltd. generated 5.94B in revenue and converted that into 1.22B in net income, yielding earnings per share of 1.21. EBITDA reached 1.38B, while operating income came in at 1.38B.
| Revenue | 5.94B |
| Gross Profit | 4.45B |
| Operating Income | 1.38B |
| Pretax Income | 1.36B |
| Net Income | 1.22B |
| EBITDA | 1.38B |
| EBIT | 1.38B |
| Earnings Per Share (EPS) | 1.21 |
Balance Sheet
Jiangsu Nhwa Pharmaceutical Co., Ltd. holds 3.69B in cash and equivalents against 84.10M in total debt, resulting in a net debt position of -1.73B. Total book value stands at 6.98B, with working capital of 5.32B providing operational flexibility.
| Cash & Cash Equivalents | 3.69B |
| Total Debt | 84.10M |
| Net Debt | -1.73B |
| Equity (Book Value) | 6.98B |
| Book Value Per Share | 6.96 |
| Working Capital | 5.32B |
Cash Flow
After subtracting -392.10M in capital expenditures, free cash flow totaled -392.10M - equivalent to -0.39 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -392.10M |
| Free Cash Flow | -392.10M |
| FCF Per Share | -0.39 |
Margins
Jiangsu Nhwa Pharmaceutical Co., Ltd. operates with a gross margin of 74.90, reflecting its pricing power and cost economics. The operating margin of 23.17 and net profit margin of 20.44 provide insight into operational efficiency.
| Gross Margin | 74.90 |
| Operating Margin | 23.17 |
| Pretax Margin | 22.95 |
| Profit Margin | 20.44 |
| EBITDA Margin | 23.17 |
Dividends & Yields
The company's payout ratio of 30.13 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.36 |
| Dividend Yield | N/A |
| Payout Ratio | 30.13 |
| Shareholder Yield | 1.67 |
| FCF Yield | 1.88 |
Stock Splits
Jiangsu Nhwa Pharmaceutical Co., Ltd.'s most recent stock split took place on May 12, 2017 with a 5:8 split ratio.
| Last Split Date | 5/12/2017 |
| Split Ratio | 5:8 |
Scores
Jiangsu Nhwa Pharmaceutical Co., Ltd. posts an Altman Z-Score of 13.95, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 13.95 |